Mizuho Adjusts Haemonetics Corporation (HAE) Estimates in Sector-Wide Review

We recently compiled a list of the 10 Best Healthcare Stocks to Buy and Hold for 3 Years. Haemonetics Corporation is among the best healthcare stocks to invest in.

TheFly reported on April 13 that Mizuho analyst Anthony Petrone reduced the price target for HAE to $70 from $80 while maintaining an Outperform rating. The revision was part of a broader update across the firm’s medical devices and diagnostics coverage ahead of upcoming first-quarter earnings. The changes reflect lowered estimates across several companies in the sector as part of the same review process.

In a separate movement, on March 30, Haemonetics Corporation (NYSE:HAE) announced that the U.S. Food and Drug Administration approved an expanded indication for its VASCADE MVP XL venous closure system. The updated label allows use with larger procedural sheaths, including 10–14F inner diameter and up to 17F outer diameter devices.

Mizuho Adjusts Haemonetics Corporation (HAE) Estimates in Sector-Wide Review

This expansion enables compatibility with advanced cardiac procedures such as pulsed field ablation and left atrial appendage closure used in treating atrial fibrillation. Regulatory approval was supported by results from the AMBULATE EXPAND clinical trial, which evaluated safety and effectiveness in patients undergoing large-sheath procedures and reported no major or minor access-site closure complications along with faster mobilization times. The update broadens the system’s clinical utility in electrophysiology and interventional procedures, removing the need for sheath downsizing and improving procedural efficiency across hospital and outpatient settings.

Haemonetics Corporation (NYSE:HAE) is a medical technology company focused on blood and plasma management solutions. It develops devices and software used in blood collection, transfusion, and therapeutic apheresis to improve safety, efficiency, and patient outcomes in healthcare systems worldwide.

While we acknowledge the risk and potential of HAE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than HAE and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Healthcare Stocks to Buy and Hold for 3 Years and 10 Best Beaten Down Stocks to Invest in According to Analysts.

Disclosure: None. Follow Insider Monkey on Google News.